A ghrelin receptor (GHS-R1A) antagonist attenuates the rewarding properties of morphine and increases opioid peptide levels in reward areas in mice.
Gut-brain hormones such as ghrelin have recently been suggested to have a role in reward regulation. Ghrelin was traditionally known to regulate food intake and body weight homoeostasis. In addition, recent work has pin-pointed that this peptide has a novel role in drug-induced reward, including morphine-induced increase in the extracellular levels of accumbal dopamine in rats. Herein the effect of the ghrelin receptor (GHS-R1A) antagonist, JMV2959, on morphine-induced activation of the mesolimbic dopamine system was investigated in mice. In addition, the effects of JMV2959 administration on opioid peptide levels in reward related areas were investigated. In the present series of experiment we showed that peripheral JMV2959 administration, at a dose with no effect per se, attenuates the ability of morphine to cause locomotor stimulation, increase the extracellular levels of accumbal dopamine and to condition a place preference in mice. JMV2959 administration significantly increased tissue levels of Met-enkephalin-Arg(6)Phe(7) in the ventral tegmental area, dynorphin B in hippocampus and Leu-enkephalin-Arg(6) in striatum. We therefore hypothesise that JMV2959 prevents morphine-induced reward via stimulation of delta receptor active peptides in striatum and ventral tegmental areas. In addition, hippocampal peptides that activate kappa receptor may be involved in JMV2959׳s ability to regulate memory formation of reward. Given that development of drug addiction depends, at least in part, of the effects of addictive drugs on the mesolimbic dopamine system the present data suggest that GHS-R1A antagonists deserve to be elucidated as novel treatment strategies of opioid addiction.
Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Jörgen A
JA
Engel
Neuropharmacology, Addiction and Behaviour, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Ingrid
I
Nylander
Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. Electronic address: elisabet.jerlhag@pharm.gu.se.
Elisabet
E
Jerlhag
D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003216:Conditioning, Operant / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D004399:Dynorphins / Q000378:metabolism; D004723:Endorphins / Q000378:metabolism; D045604:Extracellular Fluid / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D051379:Mice; D017551:Microdialysis; D009020:Morphine / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D018847:Opioid Peptides / Q000494:pharmacology*; D054440:Receptors, Ghrelin / Q000037:antagonists & inhibitors*; D012201:Reward; D014230:Triazoles / Q000494:pharmacology*
D000701:Analgesics, Opioid; D004723:Endorphins; C569751:N-(1-(4-(4-methoxybenzyl)-5-phenethyl-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)-2-aminoacetamide; D018847:Opioid Peptides; D054440:Receptors, Ghrelin; D014230:Triazoles; D004399:Dynorphins; D009020:Morphine; C036200:rimorphin; D005998:Glycine; D004298:Dopamine
Addiction; Dependence; Dopamine; Ghrelin; Opiate; Reward